Nektar Therapeutics Sued for Securities Law Violations

Contact the DJS Law Group to Discuss Your Rights

Mar. 20, 2026 at 9:34am

Got story updates? Submit your updates here. ›

The DJS Law Group has filed a class action lawsuit against Nektar Therapeutics for violations of securities laws during the class period from February 26, 2025 to December 15, 2025. The lawsuit alleges that Nektar made false and misleading statements to the market about the REZOLVE-AA study of its drug rezpegaldesleukin, which was likely to have a negative impact on the trial's results.

Why it matters

This lawsuit highlights the importance of transparency and accuracy in public disclosures by pharmaceutical companies, especially related to clinical trials that can significantly impact stock prices and investor confidence. Shareholders who purchased Nektar stock during the class period may be eligible to recover losses.

The details

According to the complaint, Nektar failed to follow protocol standards in its REZOLVE-AA study of rezpegaldesleukin, which was likely to have a negative impact on the trial's results. The lawsuit alleges that Nektar's public statements were false and materially misleading throughout the class period as a result.

  • The class period is from February 26, 2025 to December 15, 2025.
  • The deadline to join the case is May 5, 2026.

The players

Nektar Therapeutics

A biopharmaceutical company that develops innovative medicines in areas of high unmet medical need.

DJS Law Group

A law firm that specializes in securities class actions, corporate governance litigation, and domestic/international M&A appraisals, representing some of the largest and most sophisticated hedge funds and alternative asset managers in the world.

Got photos? Submit your photos here. ›

What’s next

The judge will decide on May 5, 2026 whether to allow shareholders to join the class action lawsuit against Nektar Therapeutics.

The takeaway

This case highlights the importance of pharmaceutical companies being transparent and accurate in their public disclosures, especially when it comes to clinical trials that can significantly impact stock prices and investor confidence. Shareholders who purchased Nektar stock during the class period may be able to recover their losses by joining the class action lawsuit.